This article has Open Peer Review reports available.
Fulvic acid attenuates homocysteine-induced cyclooxygenase-2 expression in human monocytes
© Chien et al.; licensee BioMed Central. 2015
Received: 19 August 2014
Accepted: 21 February 2015
Published: 13 March 2015
Homocysteine and pro-inflammatory mediators such as cyclooxygenase-2 (COX-2) have been linked to vascular dysfunction and risks of cardiovascular diseases. Fulvic acid (FA), a class of compounds of humic substances, possesses various pharmacological properties. However, the effect of FA on inflammatory responses of the monocytes remains unclear. We investigated the regulatory effect of FA on homocysteine-induced COX-2 expression in human monocytes.
Peripheral blood monocytes and U937 cells were used for all experiments. Real-time PCR and ELISA assay were used to analyze the COX-2 mRNA expression and PGE2 secretion, respectively. Specific inhibitors were used to investigate the mechanism of homocysteine-mediating COX-2 mRNA expression and PGE2 secretion. Luciferase assay, transcription factor ELISA, and chromatin immunoprecipitation were used to determine the role of nuclear factor-κB in FA-mediated inhibition of homocysteine effect on monocytes.
The results show that pretreating monocytes with FA inhibited the homocysteine-induced COX-2 expression in a dose-dependent manner. Stimulation of U937 monocytes with homocysteine induced rapid increases in the phosphorylation of ERK and JNK; the inhibitor for ERK and JNK attenuated the homocysteine-induced nuclear factor-κB activation and COX-2 expression. Transcription factor ELISA and chromatin immunoprecipitation assays showed that FA blocked the homocysteine-induced increases in the binding activity and in vivo promoter binding of nuclear factor-κB in monocytes.
Our findings provide a molecular mechanism by which FA inhibits homocysteine-induced COX-2 expression in monocytes, and a basis for using FA in pharmaceutical therapy against inflammation.
Fulvic acid (FA), a class of compounds of humic substances, is a mixture of polyphenolic acid compounds formed through the degradation of organic substances such as dead plants, microbes and animals by chemical and biological processes . FA has been reported recently to have nutraceutical properties and physiological action on the human body. It is one of the most interesting naturally occurring phytochemicals with its neuroprotective effect [2,3]. Antimicrobial and anti-inflammatory properties of FA have also been reported [4,5]. In addition, the FA extracted from peat had an antioxidant activity and an inhibitory effect on chemical mediator release in basophils . These results imply that the FA may possess a predominant role in their biological activity. Although there are a number of studies on the effect of FA on cellular and biological functions, the detailed mechanisms underlying the regulatory effect of FA remain unclear.
The formation of atherosclerotic lesions is regarded as a process of chronic inflammatory responses . Several risk factors are known to be involved in promoting atherosclerosis, including smoking, diabetes mellitus, hyperlipidemia, hypertension, and hyperhomocysteinemia. Abnormal elevation of homocysteine levels in the blood have been reported in patients with hyperhomocysteinemia . Severe hyperhomocysteinemia (plasma levels of homocysteine greater than 100 mmol/L) is found in patients with extremely premature atherosclerosis and early occlusive vascular disease . Although hyperhomocysteinemia has been considered an independent risk factor for atherosclerosis, the mechanism of causing vascular damage by homocysteine is not yet understood. Endothelial dysfunction and activation is one of the key events in vascular pathology associated with homocysteine . In addition, oxidative stress, inflammation, and smooth muscle cell proliferation, are also involved in this process.
Monocytes are the primary inflammatory cell type that infiltrates early atherosclerotic plaques. The release of pro-inflammatory mediators by monocyte-derived macrophages may play a crucial role in atherosclerotic inflammatory responses . Cyclooxygenase-2 (COX-2) is a key enzyme for the synthesis of eicosanoids. COX-2 is considerably expressed in vascular tissues due to the stimulation of pro-inflammatory factors, such as cytokines, mitogens and lipopolysaccharide . It is evident that COX-2 in activated monocytes is of particular relevance in inflammation and atherosclerosis . The activation of macrophages has been previously correlated with the induction of COX-2. Macrophages expressing COX-2 are known to produce prostaglandins that have pro-inflammatory effects, including activating chemotaxis, increasing vascular permeability, and promoting cell proliferation . Since atherosclerosis is a multifactorial disease involving a complex array of contributing factors including monocyte functions and hyperhomocysteinemia, it is necessary to investigate the effect of homocysteine on COX-2 gene expression in human monocytes. In the present study, we investigated the roles of FA in modulating homocysteine-induced COX-2 expression in primary human blood monocytes and human monocytic U937 cells, and also the molecular mechanisms underlying the regulatory effects.
All culture materials were purchased from Gibco (Grand Island, NY, USA). FA was supplied as a 20% solution by Esther Material Technology Co., Ltd., Kaohsiung, Taiwan. PD98059 (ERK inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38 inhibitor) were purchased from Calbiochem (La Jolla, CA). Mouse monoclonal antibodies (mABs) against ERK1/2, JNK1/2, phospho-ERK1/2, phospho-JNK1/2, and NF-κB p65 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Pyrrolidine dithiocarbamate (PDTC), SN50, and other chemicals of reagent grade were obtained from Sigma (St. Louis, MO).
Human monocytes from the buffy coat (Taiwan Blood Center, TBSF, Taiwan) were isolated as previously described . Peripheral blood mononuclear cells (PBMCs) were isolated by Histopaque 1077 density-gradient centrifugation. Monocytes were purified from PBMCs by negative selection using the magnetic-activated cell sorting (MACS) monocyte isolation kit (Miltenyi Biotech, Auburn, CA). The human monocytic cell line U937 was obtained from the Bioresources Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (Hsinchu, Taiwan). Cells were maintained in RPMI-1640 medium supplemented with 10% FBS.
Real-time quantitative PCR
Real-time PCR was performed, and products were detected using an ABI Prism 7900HT with the FastStart DNA SYBR Green I kit (Roche Diagnostics GMbH, Mannheim, Germany). The designed primers in this study were COX-2 forward primer, 5′-CTGAA AGATG GACGC TCAAT-3′; COX-2 reverse primer, 5′-CGTTT CAGAA GCCAG AAGAG-3′; 18S rRNA forward primer, 5′-CGGCG ACGAC CCATT CGAAC-3′, 18S rRNA reverse primer, 5′-GAATC GAACC CTGAT TCCCC GTC-3′. Quantification was performed using the 2−ΔΔCt method . All samples were measured in duplicate. The average value of both duplicates was used as the quantitative value.
The levels of PGE2 in the conditioned media were determined by using the PGE2 ELISA assay kit (R & D Systems) according to the manufacturer’s instructions .
Western blot analysis
Samples were lysed with a buffer containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and a protease inhibitor mixture (PMSF, aprotinin, and sodium orthovanadate). The protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Equal amounts of total proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) (10% running, 4% stacking), transferred onto a nitrocellulose membrane, and analyzed using the designated antibodies and the Western-Light chemiluminescent detection system (Bio-Rad).
Human COX-2 promoter constructs containing −918/+49 of COX-2 5′-flanking DNA linked to the firefly luciferase reporter gene of plasmid pGL4 (Promega, Madison, WI) were used as previously reported.16 DNA plasmids at a concentration of 1 mg/ml were transfected into DLD-1 cells by Lipofectamine (Gibco). The pSV-β-galactosidase plasmid was cotransfected to normalize the transfection efficiency. Values obtained were normalized to the levels of β-galactosidase in the cell lysates. β-galactosidase activities were determined with an assay kit and exhibited <20% variation between samples.
Transcription factor assays (TF ELISA assays)
Nuclear extracts of cells were prepared using nuclear protein extract kits (Panomics, Redwood City, CA). Equal amounts of nuclear proteins were employed for quantitative measurements of NF-κB p65 activation using commercially available ELISA kits (Panomics).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed following a published protocol . Briefly, chromatins were sheared by sonication (3 times, 10 sec on, 60 sec off). Precleared extracts were immunoprecipitated with rabbit anti-p65 and c-jun antibodies or rabbit IgG at 4°C overnight. DNA was isolated from precipitated complexes and analyzed by PCR with the following primers that amplify the part of the human COX-2 promoters that contain the NF-κB binding sites: 5′-GCCCT CCCCC GGTAT CCCAT C-3′ and 5′-AAAAA ATTGC GTAAG CCCGG T-3′. An aliquot of total input nuclear extract was used as the loading control.
The results are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was determined using an independent Student t-test for two groups of data and analysis of variance (ANOVA) followed by the Scheffe’s test for multiple comparisons. P values less than 0.05 were considered significant.
Cytotoxic effect of FA on human monocytes
FA inhibits homocysteine-induced COX-2 expression in monocytes
FA mediates homocysteine-induced COX-2 gene expression at the transcriptional level
FA-mediated inhibition of homocysteine-induced COX-2 expression is dependent on MAPK
FA-mediated inhibition of homocysteine-induced COX-2 expression is dependent on NF-κB
Monocytes are one of the main cell types that express COX-2 . Transendothelial migration of monocytes into the vessel wall is the initial step in the formation of atherosclerotic lesions. Previous study has indicated that COX-2 up-regulation was observed in peripheral blood monocytes from patients with acute myocardial infarction, suggesting that an acute inflammatory response to acute myocardial infarction is correlated with COX-2 activation in peripheral blood monocytes . In addition, the presence of COX-2 has also been reported in the shoulder region of atherosclerotic plaques, mainly colocalizing with macrophages and matrix metalloproteinases, which leads to vascular remodeling and atherothrombotic syndromes . The results of this study demonstrate that homocysteine induces both COX-2 gene expression and PGE2 secretion in human monocytes. It has been reported that homocysteine induced COX-2 expression in murine macrophages by ROS generated via NMDA receptor-mediated calcium-signaling pathways . In the present study, we found that homocysteine induced rapid increases in the phosphorylation of ERK and JNK in U937 cells. Furthermore, a specific inhibitor for ERK and JNK inhibited the homocysteine-induced COX-2 expression. These results indicate that the activation of ERK and JNK is critical for the homocysteine-induction of COX-2. Our present study further demonstrated that FA has an inhibitory effect on the homocysteine-induced ERK and JNK phosphorylation, and COX-2 expression.
The transcription factor NF-κB plays a critical role in regulating inducible gene expression in inflammatory responses. NF-κB in the promoter regions of the COX-2 gene have been shown to be essential for the responsiveness of this gene to stimuli . NF-κB dimers are retained in an inactive form in the cytosol through their interaction with IκB proteins. The interaction of pro-inflammatory factors on cells induces phosphorylation and degradation of IκB, thereby liberating NF-κB dimers that translocate into the nucleus. NF-κB then binds to DNA at specific κB sites in the promoter regions that regulate target gene expression . It has been reported that in hepatic cells, homocysteine-induced COX-2 expression is mediated via NF-κB activation . However, whether NF-κB is involved in regulating the COX-2 expression in human monocytes in response to homocysteine needs to be elucidated. The results from the TF ELISA and ChIP assays of our present study demonstrated that the homocysteine stimulation increased the in vitro DNA binding activity and the in vivo COX-2-promoter binding of NF-κB in monocytes. This activation of NF-κB-DNA binding activity, induced by homocysteine, could be significantly inhibited by pretreating monocytes with NF-κB inhibitors PDTC or SN50, which could also inhibit the homocysteine-induced COX-2 expression in monocytes. Before stimulation with homocysteine, cells pretreated with FA significantly inhibited the homocysteine-induced NF-κB-DNA binding activity, as well as in vivo NF-κB-promoter binding in monocytes. These results suggest that the homocysteine and FA may share a common pathway, i.e., NF-κB, in mediating COX-2 expression in monocytes. Our results indicate that FA exerts an anti-inflammatory function on monocytes stimulated with homocysteine. In addition, these results also suggest that this FA inhibition of COX-2 expression stimulated with homocysteine may reflect the regulatory roles of FA in gene expressions in monocytes. The present data suggest that FA may serve anti-inflammatory and atheroprotective functions by inhibiting the pro-inflammatory gene expression in monocytes in response to homocysteine stimuli.
In conclusion, FA inhibited the expression of COX-2 and production of PGE2 from homocysteine-induced monocytes. Stimulation of homocysteine in monocytes resulted in increased phosphorylation of ERK and JNK, and activation of NF-κB. FA inhibited homocysteine-induced inflammatory mediator expression by regulating the activation of these pathways.
This work was supported by grants CMRPG8A0861, CMRPG8C0941, CMRPG8C0942, CMRPF6E0021, CMRPF6E0011 and CMRPG8D1491 from Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung Memorial Hospital, and Chang Gung University of Science and Technology, Chia-Yi Campus, Taiwan, and by the National Science Council, Taiwan (NSC101-2320-B-415-003-MY3, NSC102-2314-B-750-001, NSC101-2622-B-255-001-CC3, NSC102-2313-B-255-002, and NSC102-2320-B-010 -028).
- Motojima H, O Villareal M, Han J, Isoda H. Microarray analysis of immediate-type allergy in KU812 cells in response to fulvic acid. Cytotechnology. 2011;63:181–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Cornejo A, Jiménez JM, Caballero L, Melo F, Maccioni RB. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer’s disease. J Alzheimers Dis. 2011;27:143–53.PubMedGoogle Scholar
- Guzmán-Martinez L, Farías GA, Maccioni RB. Tau oligomers as potential targets for Alzheimer’s diagnosis and novel drugs. Front Neurol. 2013;4:167.View ArticlePubMedPubMed CentralGoogle Scholar
- Van Rensburg CEJ, Malfeld SCK, Dekker J. Topical application of oxifulvic acid suppresses the cutaneous immune response in mice. Drug Dev Res. 2001;53:29–32.View ArticleGoogle Scholar
- Sherry L, Millhouse E, Lappin DF, Murray C, Culshaw S, Nile CJ, et al. Investigating the biological properties of carbohydrate derived fulvic acid (CHD-FA) as a potential novel therapy for the management of oral biofilm infections. BMC Oral Health. 2013;13:47.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamada P, Isoda H, Han JK, Talorete TP, Abe Y. Inhibitory effect of fulvic acid extracted from Canadian sphagnum peat on chemical mediator release by RBL-2H3 and KU812 cells. Biosci Biotechnol Biochem. 2007;71:1294–305.View ArticlePubMedGoogle Scholar
- Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–12.View ArticlePubMedGoogle Scholar
- Ghassibe-Sabbagh M, Platt DE, Youhanna S, Abchee AB, Stewart K, Badro DA, et al. Genetic and environmental influences on total plasma homocysteine and its role in coronary artery disease risk. Atherosclerosis. 2012;222:180–6.View ArticlePubMedGoogle Scholar
- Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005;3:1646–54.View ArticlePubMedGoogle Scholar
- Kim CS, Kim YR, Naqvi A, Kumar S, Hoffman TA, Jung SB, et al. Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc. Cardiovasc Res. 2011;92:466–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta. 2012;413:3–14.View ArticlePubMedGoogle Scholar
- Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000.View ArticlePubMedPubMed CentralGoogle Scholar
- Beloqui O, Páramo JA, Orbe J, Benito A, Colina I, Monasterio A, et al. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors? Eur Heart J. 2005;26:153–8.View ArticlePubMedGoogle Scholar
- Yeh CC, Chang SF, Huang TY, Chang HI, Kuo HC, Wu YC, et al. Shear stress modulates macrophage-induced urokinase plasminogen activator expression in human chondrocytes. Arthritis Res Ther. 2013;15:R53.View ArticlePubMedPubMed CentralGoogle Scholar
- Chang LC, Kuo HC, Chang SF, Chen HJ, Lee KF, Lin TH, et al. Regulation of ICAM-1 expression in gingival fibroblasts infected with high-glucose-treated P. gingivalis. Cell Microbiol. 2013;15:1722–34.PubMedGoogle Scholar
- Chen TC, Tsai JP, Huang HJ, Teng CC, Chien SJ, Kuo HC, et al. Regulation of cyclooxygenase-2 expression in human bladder epithelial cells infected with type I fimbriated uropathogenic E. coli. Cell Microbiol. 2011;13:1703–13.View ArticlePubMedGoogle Scholar
- Chen TC, Chien SJ, Kuo HC, Huang WS, Sheen JM, Lin TH, et al. High glucose-treated macrophages augment E-selectin expression in endothelial cells. J Biol Chem. 2011;286:25564–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Suematsu N, Ojaimi C, Kinugawa S, Wang Z, Xu X, Koller A, et al. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation. 2007;115:255–62.View ArticlePubMedGoogle Scholar
- Zhang D, Fang P, Jiang X, Nelson J, Moore JK, Kruger WD, et al. Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res. 2012;111:37–49.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou J, Werstuck GH, Lhoták S, Shi YY, Tedesco V, Trigatti B, et al. Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6 J mice. FASEB J. 2008;22:2569–78.View ArticlePubMedPubMed CentralGoogle Scholar
- Giannarelli C, Zafar MU, Badimon JJ. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism? Thromb Haemost. 2010;104:949–54.View ArticlePubMedGoogle Scholar
- Motojima H, Yamada P, Han J, Ozaki M, Shigemori H, Isoda H. Properties of fulvic acid extracted from excess sludge and its inhibiting effect on β-hexosaminidase release. Biosci Biotechnol Biochem. 2009;73:2210–6.View ArticlePubMedGoogle Scholar
- Iezzi A, Ferri C, Mezzetti A, Cipollone F. COX-2: friend or foe? Curr Pharm Des. 2007;13:1715–21.View ArticlePubMedGoogle Scholar
- Zhao SP, Deng P, Huang HG, Xu ZM, Dai HY, Hong SC, et al. Expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and its significance. Clin Chem. 2005;51:2170–3.View ArticlePubMedGoogle Scholar
- Cipollone F, Fazia M, Mezzetti A. Novel determinants of plaque instability. J Thromb Haemost. 2005;3:1962–75.View ArticlePubMedGoogle Scholar
- Lee YS, Lee SJ, Seo KW, Bae JU, Park SY, Kim CD. Homocysteine induces COX-2 expression in macrophages through ROS generated by NMDA receptor-calcium signaling pathways. Free Radic Res. 2013;47:422–31.View ArticlePubMedGoogle Scholar
- Vila-del Sol V, Fresno M. Involvement of TNF and NF-κB in the transcriptional control of cyclooxygenase-2 expression by IFN-γ in macrophages. J Immunol. 2005;174:2825–33.View ArticlePubMedGoogle Scholar
- Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011;12:715–23.View ArticlePubMedGoogle Scholar
- Wu N, Siow YL, O K. Induction of hepatic cyclooxygenase-2 by hyperhomocysteinemia via nuclear factor-κB activation. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1086–94.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.